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Aim To analyze the distribution of SLC6A4 gene polymor-
phisms in Crohn’s disease (CD) patients and their associa-
tion with the disease.
Methods We evaluated the presence/absence of promot-
er (5-HTTLPR, rs25531) and intron 2 (STin2 VNTR) polymor-
phic variants of SLC6A4 gene in a retrospective case-control 
study including 192 CD patients and 157 healthy controls 
(HC). Genotyping was performed by polymerase chain re-
action. The association of polymorphisms with CD and its 
clinical subtypes was analyzed using χ2 and Fisher exact 
test, binary logistic regression, and haplotype analysis.
Results CD patients and healthy controls had similar sex 
(88 [45.8%] vs 84 [53.5%] women, respectively; P = 0.154) 
and age (41.3 ± 12.8 years vs 41.7 ± 8.8 years, respective-
ly, P = 0.091) distribution. Significant differences were ob-
served in the STin2 genotype and allele distribution be-
tween CD patients and healthy controls (P = 0.003 and 
P = 0.002, respectively) and between the corresponding fe-
male subgroups (P = 0.004 and P = 0.007, respectively), with 
a significant negative association of biallelic ss (STin2.9 and 
Stin2.10) STin2 genotype with CD (P = 0.013, age- and sex-
adjusted odds ratio [OR] 0.5, 95% confidence interval [CI] 
0.29-0.86; women: P = 0.006, age-adjusted OR 0.32, 95% 
CI 0.14-0.72) and a significantly higher S-STin2.12 (5-HTTL-
PR/rs25531: S-STin2: STin2.12) haplotype distribution in CD 
patients (P = 0.004, OR 1.62, 95% CI 1.16-2.26). There was 
no significant association between 5-HTTLRP and rs25531 
genotype or allele frequencies and CD and between any 
SLC6A4 polymorphic loci with clinical CD subtypes.
Conclusion STin2 VNTR polymorphism of SLC6A4 gene 
may contribute to CD pathogenesis.
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Inflammatory bowel disease (IBD), with its constituent clin-
ical phenotypes, Crohn’s disease (CD) and ulcerative coli-
tis (UC), represents a major relapsing gastrointestinal (GI) 
disorder, with a combined incidence of 2-20 per 100 000 
individuals in the developed countries (1-4). IBD suscepti-
bility is influenced by a variety of factors, including genetic 
polymorphism, GI motility, stress response, visceral hyper-
sensitivity, abnormal immune response, and its reaction to 
enteromicrobial pathogens (1-4).
Neuroimmunological interactions are also important be-
cause various pro- and anti-inflammatory cytokines may 
affect neuronal activity and the release of neurotransmit-
ters influencing the activity of immuno-effector cells in 
the GI tract. The best characterized among them is sero-
tonin (5-HT), 90% of which is produced and secreted by 
intestinal enterochromaffin cells (5-8). Alterations in 5-HT 
biosynthesis, quantity, release, or clearance are important 
for both sensory signal transduction in GI motility and the 
development of visceral hypersensitivity (5-8). 5-HT is also 
a chemotactic molecule and may promote lymphocyte 
activation and secretion of pro-inflammatory cytokines 
(5-8). Therefore, upon its release and binding to targeted 
receptors, 5-HT action must be rapidly terminated. This is 
maintained by the action of serotonin re-uptake transport-
er (SERT), expressed by serotonergic neurons and the mu-
cosal enterocytes (5-8).
Animal models and studies on human cell lines and tis-
sue indicate increased 5-HT availability and reduced SERT 
expression in the inflamed colon, accompanied with an 
increased expression of inflammatory genes, thus sup-
porting the idea that the loss of SERT gene (SLC6A4) tran-
scription can either cause intestinal inflammation or result 
from it (8,9). SLC6A4 gene polymorphisms have also been 
linked with its translation and expression (10,11).
The most extensively studied among them are 5-HTTLPR, 
rs25531 (A/G) single nucleotide (SNP), and STin2 VNTR (vari-
able number of tandem repeats) polymorphic regions 
found in the promoter (5-HTTLPR and rs25531) and intron 2 
region (STin2 VNTR) of SLC6A4 gene (Figure 1) (12-19).
Sikander et al (20) has reported a significant association of 
5-HTTLPR polymorphism with UC and microscopic colitis 
(MC). However, the association between 5-HTTLPR and CD 
has never been determined. The same was true for oth-
er SLC6A4 polymorphic regions in any form of IBD (11,20). 
Therefore, the aim of this study was to compare genotype 
and allele frequencies of 5-HTTLPR, rs25531and STin2 VNTR 
FiGuRe 1. Location of SLC6A4 gene polymorphic regions and their genotype combinations examined in this study. SLC6A4 gene 
is affected by the insertion/deletion variation of the promoter region 5-HTTLPR, resulting in two alleles, long L and small S. This 
promoter region also functionally couples with the common rs25531 (A/G) single nucleotide polymorphism (SNP), resulting in alleles 
LA and LG. LA allele is associated with the higher transcriptional activity, whereas the LG allele exhibits lower serotonin uptake and the 
transcriptional activity equivalent to S allele of the 5-HTTLPR polymorphic region. Transcriptional activity of SLC6A4 gene is further 
modulated by the enhancer activity of STin2 polymorphic region, 17–18 bp long variable number of tandem repeats (VNTR), found 
in intron 2. The STin2 allelic variants were identified as 10-repeat and 12-repeat alleles that have been identified in all ethnicities, and 
the less common 9-repeat allele found only in individuals of european or African descent. Thus, promoter polymorphic region may 
be presented in biallelic, triallelic, and clustered biallelic genotype model while STin2 VNTR region may be presented in triallelic and 
biallelic genotype forms. Rare allele forms (eg, XL or STin2.7) not encountered in this study, are not presented.
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polymorphic regions in CD patients and healthy control 
participants and investigate their association with CD. Giv-
en the crucial role of SERT protein in the regulation of in-
testinal 5-HT availability, we hypothesized that the SLC6A4 
polymorphism may contribute to the genetic predisposi-
tion for the development of CD.
PATieNTS AND MeTHODS
Patients
This retrospective case-control study included all 192 con-
secutive CD patients diagnosed between December 2012 
and 2016 at the University Hospital Center Zagreb (Table 
1). CD diagnosis was established according to standard en-
doscopic, radiological, and histopathological criteria (21). 
The healthy control group consisted of 157 participants 
with no family history of IBD or irritable bowel disease. 
They were selected from 217 completely healthy volun-
tary participants (hospital employees or their acquain-
tances) and age- and sex-matched to CD patient group. 
Genetically related voluntary control participants and par-
ticipants who were incompatible according to age (out-
side the age range of CD group members) were excluded 
from further analysis. All participants signed the informed 
consent for study participation and data publication. The 
study protocol was approved by the Ethics Committee of 
the University Hospital Center Zagreb (Approval number 
04/31-JG; contract number 108-1081874-1917, start date 
January 1, 2007).
DNA extraction and genotyping
Blood samples were collected by venipuncture in EDTA 
BD Vacutainer® blood collection tubes (Becton, Dickinson 
and Company, Franklin Lakes, NJ, USA), and genomic DNA 
was isolated from peripheral blood leukocytes using the 
salting out procedure (22). Study participants were geno-
typed for both promoter and intron 2 polymorphisms of 
the SLC6A4 as previously described (22-24). Biallelic 5-HTTL-
RP variants were discriminated with some modifications as 
previously described (22-24). The following primers were 
used: forward 5′-ATG CCA GCA CCT AAC CCC TAA TGT-3’, 
reverse 5’-GGA CCG CAA GGT GGG CGG GA-3’. The 5-HT-
TLPR polymorphic region was subdivided into functional 
variants (S, LA, LG) by rs25531 (A/G) SNP using a TaqMan 
qPCR procedure according to Hu et al (25). Amplification 
was performed in a 7500 qPCR System under the follow-
ing conditions: at 50°C for 2 minutes, at 95°C for 15 sec-
onds, and at 62.5°C for 1.5 minutes. Genotype sequencing/
capillary electrophoresis (ABI PRISM 3100 Genetic Analyzer, 
TermoFisher Scientific, Waltham, MA, USA) was performed 
to acquire controls. The STin2 VNTR polymorphism was dis-
criminated using the method described by Ito et al (26). 
For the PCR reaction, the following primer pair was used: 
forward 5’-GTCAGTATCACAGGCTGCGAG-3’, reverse 5’-TGT-
TCCTAGTCTTACGCCAGTG-3’.
Statistical analysis
The normality of data distribution was analyzed by Sha-
piro-Wilk test. Data are presented as frequencies or means 
with standard deviations (±SD). The groups were com-
pared using t test or Mann-Whitney test for parametric 
and non-parametric continuous variables, respectively, 
and Pearson χ2 test for categorical variables. Conformity 
of genotype distributions to Hardy–Weinberg equilibri-
um was assessed using goodness-of-fit χ2 test. The differ-
ence in allele frequency was determined by using either 
χ2 or Fisher exact test as appropriate. Crude and adjust-
TABLe 1. Clinical characteristics of patients with Crohn’s dis-
ease (CD) analyzed in the study
No. (%) of CD patients
Characteristics total women men
Age at diagnosis (years)
≤16  21 (10.93)  5 (23.8) 16 (76.2)
17-41 153 (79.69) 76 (49.7) 77 (50.3)
>41  18 (9.38)  7 (38.9) 11 (61.1)
Disease location
ileum  60 (31.3) 29 (48.3) 31 (51.7)
colon  34 (17.7) 14 (41.2) 20 (58.8)
ileocolon  91 (47.4) 41 (45.1) 50 (54.9)
upper gastrointestinal (UGI) tract  29 (15.1) 17 (58.6) 12 (41.4)
no UGI location 157 (81.8) 68 (43.3) 89 (56.7)
Disease type
inflammatory  89 (46.4) 40 (44.9) 49 (55.1)
stricturing  64 (33.3) 31(48.4) 33 (51.6)
penetrating  39 (20.3) 17(43.6) 22 (56.4)
Perianal disease
yes  63 (32.8) 24 (38.1) 39 (61.9)
no 129 (67.2) 64(49.6) 65 (50.4)
extra-intestinal manifestation
yes  43 (22.4) 23 (53.5) 20 (44.7)
no 134 (69.8) 57 (42.54) 77 (57.46)
Family history
yes  17 (8.85)  8 (47.1)  9 (52.9)
no 175 (91.15) 80 (45.71) 95 (54.29)
Surgery
yes 105 (54.69) 45 (42.9) 60 (57.1)
no  87 (45.31) 43 (49.4) 44 (50.6)
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ed odds ratios (OR) (controlling for age and sex) and the 
corresponding 95% confidence intervals (CI) determined 
by binary logistic regression were also used to test the 
association between CD and genotype variants of both 
promoter and intron 2 SLC6A4 gene polymorphisms. As-
sociation analysis based on patient sex, or clinical CD sub-
types such as age at diagnosis, localization, and disease 
behavior were also performed. Considering that LG allele 
has the same transcriptional activity as the S allele, the tri-
allelic 5-HTTLPR-rs25531 genotypes were also coded in a 
clustered biallelic form (L’L’, L’S’ and S’S’; Figure 1). Likewise, 
the triallelic STin2 VNTR polymorphism was also coded in 
a biallelic (ll - ls - ss; Figure 1) genotype form. All biallelic 
genotype forms were analyzed under the codominant, 
dominant, and recessive model. Construction of haplo-
types, linkage disequilibrium (LD), and haplotype associ-
ation analysis were calculated by permutation test using 
the online SHEsisPlus software (27).
The power analysis (to compute a priori sample size and 
the post-hoc power of the study) was performed using 
G*Power software (version 3.1.9.2 for Windows) (28). For 
the analysis of 5-HTTLRP genotype frequencies with a χ2 
goodness-of-fit test with the small effective size (w = 0.2, 
df = 2); power (1-β) = 0.80, and α = 0.017 (Bonferroni cor-
rected P value), the required total sample size was 313 and 
actual sample size was 349. Post-hoc computed achieved 
power (1-β) of analysis was 0.085 (w = 0.2), 0.997 (w = 0.3; 
medium effective size), 1.00 (w = 0.5; large effective size) 
for genotype distribution, and 0.80 for allele frequency 
analysis (w = 0.2 - 0.5; df = 1). For the a priori analysis of 
STin2 VNTR genotype frequencies with a χ2 goodness-of-
fit test with the small effective size (w = 0.23, df = 4); power 
(1-β) = 0.80 and α = 0.008 (Bonferroni corrected P value), 
the required total sample size was 329, and the post-hoc 
achieved power (1-β) of analysis was 0.83-1.00 for geno-
type distribution and 0.99-1.00 (w = 0.2 - 0.5; df = 2) for al-
lele frequency analysis. Furthermore, with a power of 0.80 
we were able to detect an effect size of 0.223 for a signifi-
cant difference in STin2 VNTR genotype frequencies. The 
two-tailed P < 0.05 was considered significant and cor-
rected according to Bonferroni procedure (the corrected 
level of significance is: Pc = 0.05/N; N - number of indepen-
dent tests). All reported P values were uncorrected unless 
stated otherwise. Statistical analysis was performed using 
SPSS Statistics software trial version (IBM Corp., Armonk, 
NY, USA), unless stated otherwise.
ReSuLTS
Population characteristics
There were 88 (45.8%) women and 104 (54.2%) men in 
the CD group, and 84 (53.5%) women and 73 (46.5%) men 
in the control group (Pearson χ2 = 2.033, P = 0.154). The 
groups were also comparable according to age (mean±SD: 
41.3 ± 12.8 years vs 41.7 ± 8.7 years, respectively; Mann-
Whitney test, P = 0.091).
TABLe 2. 5-HTTLPR, STin2 VNTR and rs25531 SNP allele frequency distribution in patients with Crohn’s disease and healthy controls*
No. (%) of participants Pearson χ2 individual comparisons
Polymorphism CD controls χ2 P‡ χ2 P‡ OR (95% Ci)§
5-HTTLRP
L 231 (60.2) 208 (66.2)  2.74 0.098 2.74 0.098 0.77 (0.56-1.05)
S 153 (39.8) 106 (33.8) 2.74 0.098 1.30 (0.95-1.77)
rs25531
LA 212 (55.2) 185 (58.9)  3.76 0.152 0.97 0.325 0.86 (0.64-1.16)
LG  19 (5.0)  23 (7.3) 1.73 0.188 0.66 (0.35-1.23)
S 153 (39.8) 106 (33.8) 2.74 0.097 1.30 (0.95-1.77)
STin2 VNTR
12 242 (63.0) 174 (55.4) 12.03 0.002† 4.15 0.042 1.37 (1.01-1.86)
10 141 (36.7) 130 (41.4) 1.59 0.207 0.82 (0.61-1.12)
9   1 (0.3)  10 (3.2) 0.002 0.08 (0.01-0.62)
*CD – Crohn’s disease; 5-HTTLPR – serotonin reuptake transporter (SLC6A4) length polymorphic region; STin2 VNTR – variable number of tandem 
repeats (VNTR) found in intron 2 of SLC6A4 gene; rs25531 – single nucleotide (SNP) polymorphism found in the background of longer 5-HTTLPR allele 
variant; L – long 5-HTTLPR allele; S – short 5-HTTLPR allele; LA – long 5-HTTLPR allele associated with the higher transcriptional activity; LG – long 
5-HTTLPR allele exhibiting lower serotonin uptake and transcriptional activity equivalent to the short (S) allele of the 5-HTTLPR polymorphic region; 
12, 10, 9 – STin2 VNTR alleles; OR – odds ratio; Ci – confidence interval.
†Bonferroni correction Pc = 0.05/3 = 0.017.
‡Bonferroni non-adjusted P values.
§Logistic regression adjusted for age and sex.
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Association analysis
According to the Hardy-Weinberg equilibrium, there was 
no deviation in the 5-HTTLPR, STin2, and rs25531 gen-
otype distribution in CD group (5-HTTLPR: χ2 = 0.557, 
df = 1, P = 0.756; rs25531: χ2 = 1.151, df = 3, P = 0.949; STin2: 
χ2 = 0.585, df = 3, P = 0.964) and healthy control group 
(5-HTTLPR: χ2 = 0.156, df = 1, P = 0.924; rs25531: χ2 = 2.358, 
df = 3, P = 0.797; STin2 VNTR: χ2 = 7.224, df = 3, P = 0.124). 
Furthermore, allele and genotype frequencies of all poly-
morphic loci in the control group corresponded well to the 
previously published data for Croatian and other European 
populations (18,29-31).
CD group and control group showed a different distribu-
tion of STin2 VNTR allele frequencies, which remained signif-
icant after Bonferroni correction (Table 2). This was also the 
case for women with CD (χ2 = 9.850, df = 2, P = 0.007) and 
their healthy female controls (data not shown). In addition, 
STin2.12 allele showed a positive and STin2.9 allele a nega-
tive association with CD both in the overall (Table 2) patient 
sample and in the subgroup of female patients (data not 
shown). However, the association remained significant only 
for the rare STin2.9 allele in the overall study sample and the 
subgroup of female patients after Bonferroni correction (Ta-
ble 2). No significant association following Bonferroni cor-
rection was found between STin2 VNTR allele frequency and 
clinical CD subtypes (data not shown).
There was no significant association in 5-HTTLRP and 
rs25531 allele frequency between the CD and control 
group or between the corresponding sex subgroups (data 
TABLe 3. Logistic regression analysis of STIN2 VNTR genotype distribution in patients with Crohn’s disease and healthy controls*
No. (%) of participants Logistic regression
Polymorphism CD controls crude OR (95% Ci) P† OR (95% Ci)‡ P†
STin2 VNTR triallelic§ 0.038II
codominant model A 0.043II
12/12  76 (39.6)  55 (35.0) reference 1.0 reference 1.0
12/10  89 (46.4)  57 (36.3) 1.13 (0.7-1.83) 0.618 1.15 (0.71-1.86) 0.570
10/10  26 (13.5)  35 (22.3) 0.54 (0.29-0.99) 0.048 0.55 (0.30-1.02) 0.056
12/9   1 (0.5)   7 (4.5) 0.10 (0.01-0.86) 0.036 0.11 (0.013-0.89) 0.040
10/9   0 (0.0)   3 (1.9) NA 0.990 NA 0.100
codominant model B¶ 0.008** 0.009**
12/12  76 (39.6)  55 (35.0) reference 1.0 reference 1.0
12/10  89 (46.4)  57 (36.3) 1.13 (0.7-1.83) 0.618 1.15 (0.71-1.86) 0.600
10/10  26 (13.5)  35 (22.3) 0.54 (0.29-0.99) 0.048 0.55 (0.3-1.02) 0.060
9/others   1 (0.5)  10 (6.4) 0.07 (0.01-0.58) 0.014** 0.073 (0.01-0.59) 0.014**
STin2 VNTR biallelic 0.041II
codominant model 0.045II
l/l  76 (39.6)  55 (35.0) 2.02 (1.10-3.71) 0.023 1.98 (1.08-3.64) 0.028
l/s  90 (46.9)  64 (40.8) 2.06 (1.14-3.72) 0.017 2.05 (1.13-3.71) 0.018
s/s  26 (13.5)  38 (24.2) reference 1.0 reference 1.0
dominant
l/l  76 (39.6)  55 (35.0) reference 1.0 reference 1.0
l/s-s/s 116 (60.4) 102 (65.0) 0.82 (0.53-1.27) 0.380 0.84 (0.54-1.30) 0.400
recessive
l/l-l/s 166 (86.5) 119 (75.8) reference 1.0 reference 1.0
s/s  26 (13.5)  38 (24.2) 0.49 (0.28-0.85) 0.011** 0.5 (0.29-0.86) 0.013**
*CD – Crohn’s disease; STin2 VNTR – variable number of tandem repeats (VNTR) found in intron 2 of serotonin reuptake transporter (SLC6A4) gene; 
OR – odds ratio; Ci – confidence interval. l – Long (12) STin2 alleles; s – short (10, 9) STin2 alleles; 12, 10, 9: STin2 VNTR alleles.
†Bonferroni non-adjusted P values.
‡Logistic regression adjusted for age and sex.
§Overall STin2 VNTR genotype distribution in CD patients and healthy controls: χ2 = 15.857, df = 4, P = 0.003.
iiGlobal P value for logistic regression analysis.
¶Rare genotype variants grouped together.
**Significant P values (<Pc). Bonferroni correction for genotype distribution analysis Pc = 0.008 (0.05/6 – number of genotypes) and for logistic regres-
sion analysis Pc = 0.017 (0.05/3 – number of genetic model comparisons).
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not shown). The results remained the same after the analy-
sis for clinical CD subtypes (data not shown). Nevertheless, 
we did observe a positive, although non-significant, asso-
ciation of S allele of 5-HTTLRP and rs25531 polymorphism 
with CD (Table 2).
Pearson χ2 test showed significant differences in STin2 
genotype distribution (Table 3) between CD patients and 
healthy controls (P = 0.003) and between the correspond-
ing female (χ2 = 15.326, df = 4, P = 0.004) subgroups (data 
not shown). This was even more pronounced when car-
riers of the rare STin2 genotype forms (STin2 12/9 + STin2 
10/9; Fisher exact test for CD vs controls; P = 0.002) were 
grouped together (overall CD: χ2 = 15.720, df = 3, P = 0.001; 
female subgroup: χ2 = 15.326, df = 3, P = 0.002). Further-
more, STin2 12/12 and Stin2 12/10 genotypes were more 
common, while STin2 10/10 genotype was less common 
among CD patients and controls. The same was true when 
we analyzed the corresponding female subgroups only 
(data not shown). However, even at very liberal correction 
for multiple comparisons of Pc = 0.008 (Pc = 0.05/N – num-
ber of genotypes analyzed), we did not find any significant 
difference in the distribution of individual STin2 VNTR gen-
otypes between CD and controls (Table 3).
In logistic regression analysis, the co-dominant triallelic 
STin2 genotype model did not show a significant associa-
tion of individual STin2 genotypes with CD (Table 3). How-
TABLe 4. Logistic regression analysis of 5-HTTLRP and rs25531 genotype distribution in patients with Crohn’s disease and healthy 
controls*
No. (%) of participants Logistic regression
Polymorphism CD controls crude OR (95% Ci) P† OR (95% Ci) ‡ P†
5-HTTLRP biallelic§ 0.180II 0.200II
codominant
L/L  67 (34.9)  70 (44.6) reference 1.0 reference 1.0
L/S  97 (50.5)  68 (43.3) 1.50 (0.94-2.35) 0.090 1.48 (0.94-2.35) 0.090
S/S  28 (14.6)  19 (12.1) 1.54 (0.79-3.02) 0.210 1.52 (0.77-2.98) 0.230
dominant  
L/L  67 (34.9)  70 (44.6) reference 1.0 reference 1.0
L/S-S/S 125 (65.1)  87 (55.4) 1.50 (0.97-2.31) 0.070 1.49 (0.97-2.30) 0.070
recessive
L/L-L/S 164 (85.4) 138 (87.9) reference 1.0 reference 1.0
S/S  28 (14.6)  19 (12.1) 1.24 (0.66-2.32) 0.500 1.22 (0.65-2.29) 0.530
5-HTTLRP/rs25531 triallelic¶ 0.670II 0.670II
codominant
LA/LA  57 (29.7)  57 (36.3) reference 1.0 reference 1.0
LA/LG  10 (5.2)  11 (7.0) 0.91 (0.36-2.31) 0.840 0.91 (0.36-2.31) 0.840
LA/S  88 (45.8)  60 (38.2) 1.47 (0.90-2.40) 0.130 1.47 (0.90-2.41) 0.130
LG/S   9 (4.7)   8 (5.1) 1.13 (0.41-3.12) 0.820 1.07 (0.38-2.98) 0.900
LG/LG   0 (0.0)   2 (1.3) NA 0.990 NA 0.100
S/S  28 (14.6)  19 (12.1) 1.47 (0.74-2.93) 0.270 1.46 (0.73-2.90) 0.290
5-HTTLRP/rs25531 biallelic 0.410II 0.410II
codominant
L’/L’  57 (29.7)  57 (36.3) reference 1.0 reference 1.0
L’/S’  98 (51.0  71 (45.2) 1.38 (0.86-2.23) 0.190 1.39 (0.86-2.24) 0.180
S’/S’  37 (19.3)  29 (18.5) 1.28 (0.69-2.35) 0.430 1.25 (0.68-2.31) 0.470
dominant
L’/L’  57 (29.7)  57 (36.3) reference 1.0 reference 1.0
L’/S’- S’/S’ 135 (70.3) 100 (63.7) 1.35 (0.86-2.12) 0.190 1.346 (0.86-2.11) 0.200
recessive
L’/L’- L’/S’ 155 (80.7) 128 (81.5) reference 1.0 reference 1.0
S’/S’  37 (19.3)  29 (18.5) 1.05 (0.61-1.81) 0.850 1.032 (0.60-1.77) 0.910
*CD – Crohn’s disease; 5-HTTLPR – serotonin reuptake transporter (SLC6A4) length polymorphic region; rs25531 – single nucleotide (SNP) polymor-
phism found in the background of longer 5-HTTLPR allele variant; L’: LA; S’: LG or S (clustered biallelic 5-HTTLRP/rs25531 model based on transcriptional 
activity: L’/L’>L’/S’>S’/ S’) OR – odds ratio, Ci – confidence interval.
†Bonferroni non-adjusted P values; Bonferroni correction for genotype distribution analysis Pc = 0.0083 (0.05/6 - number of genotypes) and for logis-
tic regression analysis Pc = 0.0166 (0.05/3 - number of genetic model comparisons).
‡Logistic regression adjusted for age and sex.
§Overall 5-HTTLRP genotype distribution between CD and healthy control group: χ2 = 3.410, df = 2, P = 0.182;
iiglobal P value of logistic regression analysis.
¶Overall triallelic 5-HTTLRP/rs25531 genotype distribution between CD and healthy control group: χ2 = 5.674, df = 5, P = 0.339.
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ever, when men and women were analyzed together un-
der the recessive biallelic model (Table 3) or when women 
only were analyzed (data not shown), carriers of biallel-
ic ss (s = STin2 10 or STin2 9), STin2 genotype form exhib-
ited a significant negative association with CD compared 
with ll and ls carriers (female patients: Wald = 7.564, df = 1, 
P = 0.006, age-adjusted OR = 0.32, 95% CI = 0.14-0.72), 
which remained significant after sex and/or age adjust-
ment (female patients: Wald = 7.564, df = 1, P = 0.006, OR 
adjusted by age = 0.32, 95% CI = 0.14-0.72). Nevertheless, 
only the variation of co-dominant STin2 model in which 
the rare genotypes (STin2 12/9 and 10/9) were grouped to-
gether showed significant global P values in crude and ad-
justed logistic regression analysis, and only when male and 
female patients were analyzed together (Table 3).
No significant difference was observed in 5-HTTLRP and 
rs25531 genotype distribution between CD group and 
controls (Table 4) or between sex subgroups and clinical 
CD subtypes (data not shown). The same was found when 
biallelic 5-HTTLRP and rs25531 genotype forms were ana-
lyzed under the codominant, dominant, or recessive ge-
netic model. Nevertheless, we did observe more frequent, 
although non-significant, distribution of heterozygous (LS, 
LALG, L’S’) and homozygous SS genotype forms in the CD 
group (Table 4).
TABLe 5. The frequency of SLC6A4 haplotypes in patients with Crohn’s disease and their healthy controls*
SLC6A4 haplotypes No. (%) of participants
5-HTTLRP rs25531 STin2 VNTR CD controls χ2 P† OR (95% Ci)†
L LA STin2 10 110 (28.6) 97 (30.8) 0.417 0.518 0.89 (0.65-1.24)
S - STin2 12 131 (34.1) 76 (24.2) 8.133 0.004‡ 1.62 (1.16-2.26)
L LA STin2 12 102 (26.5) 88 (28.0) 0.186 0.665 0.93(0.66-1.30)
L LG STin2 10   9 (2.3)  6 (1.9) 0.153 0.694 1.23 (0.43-3.50)
S - STin2 10  22 (5.7) 27 (8.5) 2.179 0.139 0.65 (0.36-1.16)
L LG STin2 12   9 (2.3)  10 (3.1) 0.461 0.496 0.73 (0.29-1.82)
L LG STin2 9   1 (0.2)  7 (2.2) 5.910 0.015 0.11 (0.01-0.94)
S - STin2 9   0 (0.0)  3 (0.9) 3.684 0.054 NA
* CD – Crohn’s disease; 5-HTTLPR – serotonin reuptake transporter (SeRT/SLC6A4) length polymorphic region; STin2 VNTR – variable number of 
tandem repeats (VNTR) found in intron 2 of SLC6A4 gene; rs25531 – single nucleotide (SNP) polymorphism found in the background of longer 
5-HTTLPR allele variant; LG – Long 5-HTTLPR allele exhibiting lower serotonin uptake and transcriptional activity equivalent to the short (S) allele of 
the 5-HTTLPR polymorphic region; LG – Long 5-HTTLPR allele exhibiting lower serotonin uptake and transcriptional activity equivalent to the short (S) 
allele of the 5-HTTLPR polymorphic region; Global result – Pearson χ2 = 18.29, Pearson P = 0.011; OR – odds ratio; Ci – confidence interval.
†Bonferroni non-adjusted P values and confidence intervals; Bonferroni correction for haplotype analysis: Pc = 0.006 (0.05/8 - number of haplotype 
comparisons).
‡Significant P value (<Pc).
FiGuRe 2. Linkage disequilibrium (LD) in SLC6A4 gene with D’ and r2 values.
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Haplotype analysis
5-HTTLPR and rs25531 polymorphic region were in strong 
linkage disequilibrium, while LDs between them and STin2 
VNTR polymorphic region were relatively weak (Figure 2). 
After Bonferroni correction, only S-S-STin2.12 haplotype 
showed a significantly higher frequency in CD group (Table 
5). The higher frequency in CD group was also revealed for 
L-LG-STin2.10 haplotype, but it was not significant (Table 5).
DiSCuSSiON
Our data revealed a significant difference in STin2 VNTR 
genotype and allele distribution between the overall CD 
group and healthy controls and between the female pa-
tient group and the corresponding control group. There 
was also a significant negative association of biallelic ss 
(STin2. 10/10 and STin2. 10/9 vs STin2. 12/12, 12/10 and 12/9 
combined) genotype form and CD. We also found a sig-
nificantly higher S-STin2.12 (5-HTTLPR/rs25531: S - STin2: 
STin2.12) haplotype distribution among CD patients. How-
ever, we did not find any association between 5-HTTLRP 
and rs25531 genotype or allele frequencies and CD or 
between any SLC6A4 polymorphic loci and clinical sub-
types of CD. Nevertheless, our results indicate that STin2 
VNTR polymorphism of SLC6A4 gene may contribute to CD 
pathogenesis.
Altered function and down-regulation of SERT protein 
expression paralleled with abnormal 5-HT concentra-
tion, both locally in epithelial layer and in the circulation, 
has been documented in several human GI inflammatory 
conditions including CD, UC, and MC, as well as diverticu-
litis and active celiac disease (32-34). This was also doc-
umented in several animal models of intestinal inflam-
mation (35-39). Pro-inflammatory mediators and growth 
factors released during IBD may down-regulate SLC6A4 
transcription and decrease SERT protein expression and 
function (40-43).
Another possibility is that some individuals with IBD have a 
genetic predisposition leading to altered SERT expression 
with consequent changes in gastrointestinal 5-HT levels, 
which contributes indirectly to pro-inflammatory condi-
tions in the affected intestinal mucosa.
However, despite the recognition that intestinal inflamma-
tory diseases, such as CD, can have a strong genetic com-
ponent, polymorphisms so far linked with SERT transporter 
have not been associated with CD.
Furthermore, in previous reports on GI diseases only STin2 
VNTR was observed as an attractive candidate for a possible 
association of the SERT with IBS (10,44). Although IBD and 
IBS are usually viewed as dichotomous conditions, they 
exhibit similar alterations in serotonergic-signaling mech-
anisms (33,44-46). Due to the development of IBS symp-
toms in IBD patients in remission and the clinical overlap 
between IBD and IBS, some authors even argued that they 
may represent clinical manifestations of a pathophysiolog-
ic spectrum of the same disease (47,48). Several population 
studies showed that IBS patients have an increased risk of 
becoming IBD patients than patients without prior IBS his-
tory, and this effect may be greater for CD (49,50).
Reports regarding the link between STin2 polymorphism 
and IBS were controversial and inconclusive, with most of 
them indicating no association with IBS or its clinical sub-
types (47). However, Wang et al (51) found that IBS patients 
had a greater frequency of STin2.12/10 and a lower fre-
quency of STin2.12/12 genotype compared to controls, but 
identified no significant difference in STin2 polymorphism 
among different clinical subtypes of IBS.
Current research in functional implications of the STin2 
polymorphism is also inconclusive. It is known that STin2 
acts as a transcriptional regulator and has allele-dependent 
enhancer-like properties that may influence tissue-specifc 
regulation of SLC6A4 gene (18,52). However, it seems that 
individual SLC6A4 polymorphisms have a weak influence 
compared with the combined effect of 5-HTTLPR and STin2 
region (14,18,52,53). Therefore, their allelic combinations 
should be identified before concluding about functional 
and phenotypic associations. LD between these two loci, 
ranging from moderate (European) to very strong (Native 
Americans), was found in most of the studied populations 
(31). In addition, a partial linkage of STin2.12 allele with S 
allele of 5-HTTLPR (S12 haplotype combination) has been 
reported and had stronger enhancer-like properties on 
SLC6A4 transcription than L10 or S10 haplotype (53,54). We 
found a significantly higher distribution of S12 haplotype 
in CD group, showing its positive association with disease 
occurrence. However, since we did not measure the lev-
el of SERT expression or 5-HTT plasma or tissue levels, we 
were not able to indicate any functional consequences of 
this finding.
We did not confirm the association of 5-HTTLRP and 
rs25531 with CD occurrence, but we did observe the 
tendency toward higher frequencies of heterozygote 
5-HTTLRP and rs25531 genotype forms in CD group. 
CLINICAL SCIENCE240 Croat Med J. 2018;59:232-43
www.cmj.hr
This effect of molecular heterosis was also described in 
some other studies of 5-HTTLPR (55-57).
To the best of our knowledge, there are no reports ana-
lyzing the relationship between the promoter polymor-
phic regions of the SLC6A4 gene with CD. Sikander et al 
(20) demonstrated a potential association between 5-HT-
TLPR polymorphism and UC and MC by finding a signif-
icantly lower frequency of SS vs non-SS (LL and LS com-
bined) 5-HTTLPR genotypes in MC patients or UC patients 
in remission and significantly higher serum 5-HT levels 
(SS>LS>LL) in these two patient groups. This was especially 
the case in MC LS and SS genotype carriers compared with 
controls (20). In addition, UC patients with active disease 
and SS genotype also had increased 5-HT levels compared 
with control subjects expressing the same genotype (20). 
Similar to our results in CD patients, they did not observe 
any significant differences in 5-HTTLPR genotype and allele 
distributions between UC patients with active disease and 
healthy controls or between male and female patient sub-
groups (20). Likewise, Shiotani et al (34) also observed no 
significant association of 5-HTTLPR variants and UC. Our re-
sults were contrary to the findings of Sikander et al (20), as 
we found a higher frequency of SS genotype in CD group.
The observed discrepancies are possibly due to hetero-
geneous background of CD and other forms of IBD and/
or ethnical or regional differences between the studied 
groups. They are also consistent with the previously men-
tioned hypothesis that 5-HTTLPR might represent only one 
of the contributing polymorphic factors responsible for 
the disease occurrence.
Regarding the IBS and 5-HTTLRP polymorphism, different 
associations were reported, but the results were contradic-
tory and inconclusive even for the same population under 
the study. The most recent meta-analysis found no signifi-
cant association between 5-HTTLPR and IBS in overall pop-
ulation, while in the IBS subtype- and ethnic subgroup-
based analysis the LL genotype was demonstrated as a risk 
factor for constipation predominant IBS (58).
With respect to rs25531 polymorphism, we found only two 
studies examining its association with IBS, and only one re-
ported a positive association with disease occurrence with 
three times higher odds ratio for the LG allele distribution 
in IBS patients compared to controls (59,60).
There are several limitations to our study. The sample 
size was too small for a comprehensive genotype 
analysis, so the results cannot be generalized and should 
be interpreted cautiously. Second, we did not determine 
the 5-HT levels and were unable to evaluate the functional 
consequences of individual genotype or haplotype vari-
ants on SERT expression. Third, association studies of unre-
lated individuals, such as ours, warrant cautious interpreta-
tion as unknown sources of population stratification may 
affect the results.
In conclusion, we demonstrated significant differences in 
STin2 genotype and allele distribution between CD pa-
tients and healthy controls, and a negative association of 
biallelic ss STin2 genotype variant and a positive associa-
tion of S12 haplotype with CD disease. Further large-scale 
studies in this and other populations aimed to confirm the 
obtained results and decipher the exact functional role of 
STin2 VNTR polymorphic region in intestinal inflammatory 
diseases are warranted.
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